Gilead Sciences Inc (GILD)

Feb 20, 2025, 4:30 PM EST - 2 days ago

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Feb 19, 2025, 4:05 PM EST - 3 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 18, 2025, 12:59 PM EST - 4 days ago

Calls of the Day: Gilead Sciences and Merck

MRK

Feb 18, 2025, 8:30 AM EST - 4 days ago

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Feb 14, 2025, 1:31 PM EST - 8 days ago

Josh Brown's best stocks

CTVA UNP

Feb 12, 2025, 3:22 PM EST - 10 days ago

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Feb 12, 2025, 8:25 AM EST - 10 days ago

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

Feb 11, 2025, 8:40 PM EST - 10 days ago

Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:08 PM EST - 11 days ago

Gilead quarterly results beat estimates

Feb 11, 2025, 4:05 PM EST - 11 days ago

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

Feb 11, 2025, 4:02 PM EST - 11 days ago

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 3:04 AM EST - 11 days ago

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Feb 7, 2025, 12:56 PM EST - 15 days ago

KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited

Feb 5, 2025, 6:32 PM EST - 16 days ago

Final Trade: UBER, MP, MGNI, GILD

UBER MGNI MP

Feb 3, 2025, 4:56 PM EST - 19 days ago

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 3, 2025, 10:36 AM EST - 19 days ago

Trump gives a lift to healthcare stocks with comments on Medicare and Medicaid

ABBV CNC ELV HCA MOH

Jan 31, 2025, 3:31 PM EST - 22 days ago

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

BMY MRK

Jan 30, 2025, 8:00 AM EST - 23 days ago

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

CTSH

Jan 28, 2025, 4:05 PM EST - 25 days ago

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 15, 2025, 3:45 PM EST - 5 weeks ago

Gilead Sciences, US government settle patent case over HIV prevention drugs

Jan 13, 2025, 6:32 PM EST - 5 weeks ago

Final Trade: ANF, GILD

ANF

Jan 13, 2025, 6:10 PM EST - 5 weeks ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GSK IBB

Jan 13, 2025, 5:09 PM EST - 5 weeks ago

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Jan 13, 2025, 11:15 AM EST - 5 weeks ago

Gilead CEO on funding for new HIV prevention medicine

Jan 13, 2025, 11:11 AM EST - 5 weeks ago

Gilead's new HIV prevention drug lenacapavir will ‘change the face of HIV,' says CEO Daniel O'Day

Jan 13, 2025, 9:01 AM EST - 5 weeks ago

Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV

Jan 11, 2025, 12:40 PM EST - 6 weeks ago

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Jan 11, 2025, 11:00 AM EST - 6 weeks ago

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Dec 29, 2024, 3:51 AM EST - 7 weeks ago

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 20, 2024, 4:05 PM EST - 2 months ago

Gilead Sciences to Present at Upcoming Investor Conference

Dec 18, 2024, 1:53 AM EST - 2 months ago

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 17, 2024, 8:30 AM EST - 2 months ago

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Dec 17, 2024, 7:00 AM EST - 2 months ago

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

Dec 13, 2024, 6:37 AM EST - 2 months ago

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Dec 12, 2024, 5:54 PM EST - 2 months ago

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

SNY

Dec 12, 2024, 5:30 PM EST - 2 months ago

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Dec 10, 2024, 6:50 PM EST - 2 months ago

Final Trade: LMAT, GOOGL, IBM, GILD

GOOG GOOGL IBM LMAT

Dec 9, 2024, 5:45 PM EST - 2 months ago

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Dec 9, 2024, 4:30 PM EST - 2 months ago

Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Dec 8, 2024, 12:30 PM EST - 2 months ago

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Dec 4, 2024, 2:39 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Dec 3, 2024, 1:47 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Dec 3, 2024, 7:00 AM EST - 2 months ago

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

Nov 27, 2024, 5:00 PM EST - 3 months ago

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Nov 26, 2024, 1:28 PM EST - 3 months ago

The Best Large-Cap Stocks to Buy

ABT AMGN BSX CRM GS INTU MDT

Nov 22, 2024, 4:24 PM EST - 3 months ago

The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.

Nov 20, 2024, 11:45 AM EST - 3 months ago

Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)

Nov 15, 2024, 2:14 PM EST - 3 months ago

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Nov 15, 2024, 11:00 AM EST - 3 months ago

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Nov 14, 2024, 12:52 AM EST - 3 months ago

Gilead Sciences to close Seattle office; shutdown impacts 72 employees